Nicholas A.J. Botwood

Syndax Pharmaceuticals R&D head sells 65,515 shares for $1.2M under 10b5-1 plan as stock falls 22.3% in 90 days

Nicholas A.J. Botwood, Head of R&D and CMO at Syndax, executed 2 separate sales totaling 65,515 shares for $1,183,642.90 at blended average price $18.07 on 2026-06-11 and 2026-06-12. This sale represents a 51.8% reduction in his pre-transaction holdings of 126,400 shares, leaving him with 60,885 shares post-transaction. The sales were scheduled under a 10b5-1 trading plan rather than discretionary decisions. Against the current price of $18.25, the stock is down 22.3% over the prior 90 days and down 28.7% from its 52-week high of $25.59. The company remains unprofitable with net income of $-42,673,000.00 in the latest quarter, despite significant revenue growth of 627.8% year-over-year to $64,864,000.00. His prior purchase at this same ticker on 2025-05-16 showed 90-day returns of 63.8%, but his current planned sales occur amid material stock weakness and ongoing operational losses.

Head of R&D at unprofitable SNDX buys 11,765 shares ($105.8K) at $9.00; 3 other insiders also bought in past 14 days.

Botwood Nicholas A.J., Head of R&D and CMO, purchased 11,765 shares for $105,826.18, expanding his holdings by 50.3% to 35,165 shares total. The transaction occurs amid significant price weakness: the stock trades at $9.30, down 62.5% from its 52-week high of $24.81 and down 19.4% over the past 30 days. Critically, the company reported net income of $-84,846,000.00 on revenue of $20,042,000.00, reflecting material unprofitability. The cluster signal—three other insiders also purchasing within the past 14 days—indicates coordinated accumulation by the insider group despite operational losses and depressed equity valuation. This pattern is worth monitoring to determine whether it reflects confidence in an inflection point or simply takes advantage of depressed pricing.